Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ADXN 
Addex Therapeutics Ltd (ADXN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/14/2025: ADXN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $30
1 Year Target Price $30
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -54.5% | Avg. Invested days 24 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 8.32M USD | Price to earnings Ratio - | 1Y Target Price 30 |
Price to earnings Ratio - | 1Y Target Price 30 | ||
Volume (30-day avg) 1 | Beta 1.77 | 52 Weeks Range 6.51 - 12.05 | Updated Date 10/14/2025 |
52 Weeks Range 6.51 - 12.05 | Updated Date 10/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -8.95 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -2014.84% |
Management Effectiveness
Return on Assets (TTM) -13.55% | Return on Equity (TTM) -61.91% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 5918008 | Price to Sales(TTM) 49.73 |
Enterprise Value 5918008 | Price to Sales(TTM) 49.73 | ||
Enterprise Value to Revenue 85.22 | Enterprise Value to EBITDA -0.76 | Shares Outstanding 927066 | Shares Floating 39007954 |
Shares Outstanding 927066 | Shares Floating 39007954 | ||
Percent Insiders - | Percent Institutions 0.04 |
Upturn AI SWOT
Addex Therapeutics Ltd
Company Overview
History and Background
Addex Therapeutics Ltd is a biopharmaceutical company pioneering allosteric modulation-based therapies for neurological disorders. Founded in 2002, it focuses on developing orally available, small-molecule allosteric modulators.
Core Business Areas
- mGluR4 PAM Program: Developing selective positive allosteric modulators (PAMs) of metabotropic glutamate receptor 4 (mGluR4) for Parkinson's disease and other neurological conditions.
- GABABR PAM Program: Developing positive allosteric modulators of the GABA-B receptor (GABABR) for treating Charcot-Marie-Tooth disease type 1A (CMT1A) and other disorders.
Leadership and Structure
Tim Dyer serves as the CEO. The company's structure includes research and development, clinical operations, and corporate functions.
Top Products and Market Share
Key Offerings
- Dipraglurant: A mGluR5 negative allosteric modulator (NAM) in development for dystonia; currently partnered. Market share and revenue data are not publicly disclosed by Addex, as it is still in development. Competitors include companies developing alternative treatments for dystonia, such as botulinum toxin therapies and deep brain stimulation.
- ADX71441: An mGluR2 positive allosteric modulator (PAM), licensed to Janssen Pharmaceuticals. Market share and revenue data are not publicly disclosed by Addex, as it is still Janssen's development. Competitors include companies developing alternative treatments for schizophrenia and other psychiatric disorders.
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive, with significant investments in research and development. The focus is on developing novel therapeutics for various diseases.
Positioning
Addex is a specialist in allosteric modulation, a differentiated approach in drug discovery, giving them a competitive edge in specific neurological indications.
Total Addressable Market (TAM)
The total addressable market for Addex's target indications, such as Parkinson's and CMT1A, is substantial, potentially reaching billions of dollars. Addex is aiming to capture a portion of this TAM through innovative therapies.
Upturn SWOT Analysis
Strengths
- Proprietary allosteric modulation platform
- Strong pipeline of novel drug candidates
- Partnerships with major pharmaceutical companies
- Experienced management team
Weaknesses
- Limited financial resources
- Dependence on partnerships for revenue
- High risk of clinical trial failures
- Lack of commercialization infrastructure
Opportunities
- Expanding pipeline through new drug discovery
- Securing additional partnerships
- Advancing existing drug candidates through clinical trials
- Addressing unmet medical needs in neurological disorders
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Patent expirations
- Economic downturn
Competitors and Market Share
Key Competitors
- LLY
- VRTS
- TEVA
Competitive Landscape
Addex has a competitive advantage in allosteric modulation but faces challenges from larger pharmaceutical companies with greater resources.
Growth Trajectory and Initiatives
Historical Growth: Addex's growth has been driven by its pipeline advancement and partnerships.
Future Projections: Future growth depends on clinical trial success and securing additional partnerships. Analyst estimates are required.
Recent Initiatives: Recent initiatives include advancing clinical trials for key drug candidates and seeking new partnerships.
Summary
Addex Therapeutics is a biopharmaceutical company with a promising allosteric modulation platform and several drug candidates in development. The company's partnerships are crucial for its financial sustainability. Clinical trial success and securing new partnerships will be key to its future growth. Addex faces competition from larger pharmaceutical companies and the inherent risks of drug development.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Third-Party Market Research Reports
- Publicly Available Information
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market share data and financial estimates are based on available information and may not be precise. Information is current up to the date of this response.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Addex Therapeutics Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2020-01-29 | Co-Founder, CEO & Director Mr. Timothy Mark Dyer | ||
Sector Healthcare | Industry Biotechnology | Full time employees 2 | |
Full time employees 2 | |||
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant, which is in phase 1 clinical trial for the treatment of post-stroke/TBI recovery, as well as to treat Parkinson's disease levodopa-induced dyskinesia. The company also develops ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM); and GABAB PAM for the treatment pain, anxiety, addiction, cough, and overactive bladder. It has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the develop mGlu2 PAM compounds for the treatment of human health; and license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.